Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Metopirone
Metyrapone is a diagnostic medication used to evaluate the function of the hypothalamic-pituitary-adrenal (HPA) axis. It works by inhibiting the enzyme 11β-hydroxylase, which is crucial for the final step in cortisol synthesis in the adrenal glands. This inhibition leads to a decrease in cortisol levels, triggering the release of corticotropin-releasing hormone (CRH) from the hypothalamus and adrenocorticotropic hormone (ACTH) from the pituitary gland. By measuring the ACTH response, clinicians can assess the integrity of the HPA axis and diagnose conditions such as adrenal insufficiency or Cushing's syndrome.
Used to diagnose adrenal insufficiency and Cushing's syndrome.
Outcome:
Increased risk of adrenal insufficiency
Mechanism:
Both drugs inhibit cortisol synthesis.
Outcome:
Altered cortisol response to metyrapone
Mechanism:
Effect on HPA axis regulation.
Outcome:
Potential for increased bleeding risk
Mechanism:
Both drugs can affect platelet function.
New diagnostic tests using metyrapone in combination with other biomarkers are likely to be developed within the next 5 years (70% confidence).
Based on historical usage and safety data, metyrapone is expected to maintain its current regulatory status.
Diagnostic Agent, Endocrine Agent
Pyridylalkane